DiaMedica Therapeutics Inc (DMAC) - Net Assets
Based on the latest financial reports, DiaMedica Therapeutics Inc (DMAC) has net assets worth $56.11 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($61.37 Million) and total liabilities ($5.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check DiaMedica Therapeutics Inc (DMAC) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $56.11 Million |
| % of Total Assets | 91.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | 27.46% |
| 10-Year Change | 4403.34% |
| Growth Volatility | 499.54 |
DiaMedica Therapeutics Inc - Net Assets Trend (2004–2025)
This chart illustrates how DiaMedica Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore DiaMedica Therapeutics Inc total assets for the complete picture of this company's asset base.
Annual Net Assets for DiaMedica Therapeutics Inc (2004–2025)
The table below shows the annual net assets of DiaMedica Therapeutics Inc from 2004 to 2025. For live valuation and market cap data, see DMAC company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $56.11 Million | +37.80% |
| 2024-12-31 | $40.72 Million | -20.25% |
| 2023-12-31 | $51.06 Million | +60.42% |
| 2022-12-31 | $31.83 Million | -27.71% |
| 2021-12-31 | $44.02 Million | +69.23% |
| 2020-12-31 | $26.01 Million | +241.53% |
| 2019-12-31 | $7.62 Million | -55.26% |
| 2018-12-31 | $17.02 Million | +2030.79% |
| 2017-12-31 | $799.00K | -35.87% |
| 2016-12-31 | $1.25 Million | +201.34% |
| 2015-12-31 | $-1.23 Million | +19.58% |
| 2014-12-31 | $-1.53 Million | -210.66% |
| 2013-12-31 | $1.38 Million | -38.99% |
| 2012-12-31 | $2.26 Million | -62.01% |
| 2011-12-31 | $5.96 Million | -30.05% |
| 2010-12-31 | $8.52 Million | +713.60% |
| 2009-12-31 | $1.05 Million | -62.31% |
| 2008-12-31 | $2.78 Million | -31.62% |
| 2007-12-31 | $4.06 Million | +521.91% |
| 2006-12-31 | $653.60K | +29.14% |
| 2005-12-31 | $506.11K | +147.74% |
| 2004-12-31 | $-1.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to DiaMedica Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17079792247.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $50.00K | 0.09% |
| Other Components | $228.83 Million | 407.81% |
| Total Equity | $56.11 Million | 100.00% |
DiaMedica Therapeutics Inc Competitors by Market Cap
The table below lists competitors of DiaMedica Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Coremax Corp
TW:4739
|
$333.02 Million |
|
Benchmark Metals Inc
V:CEI
|
$333.03 Million |
|
Forrestania Resources Ltd
AU:FRS
|
$333.23 Million |
|
Yuen Foong Yu Consumer Prod
TW:6790
|
$333.27 Million |
|
Sichuan Langsha Holding Ltd
SHG:600137
|
$332.89 Million |
|
Grupo Traxión S.A.B. de C.V
MX:TRAXIONA
|
$332.85 Million |
|
ANGLO ASIAN MINING
F:A4A
|
$332.85 Million |
|
Rapid7 Inc
NASDAQ:RPD
|
$332.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DiaMedica Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 40,718,000 to 56,111,000, a change of 15,393,000 (37.8%).
- Net loss of 32,766,000 reduced equity.
- New share issuances of 43,282,000 increased equity.
- Other comprehensive income increased equity by 27,000.
- Other factors increased equity by 4,850,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-32.77 Million | -58.39% |
| Share Issuances | $43.28 Million | +77.14% |
| Other Comprehensive Income | $27.00K | +0.05% |
| Other Changes | $4.85 Million | +8.64% |
| Total Change | $- | 37.80% |
Book Value vs Market Value Analysis
This analysis compares DiaMedica Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.17x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $-0.04 | $6.18 | x |
| 2005-12-31 | $0.58 | $6.18 | x |
| 2006-12-31 | $0.75 | $6.18 | x |
| 2007-12-31 | $5.07 | $6.18 | x |
| 2008-12-31 | $3.06 | $6.18 | x |
| 2009-12-31 | $1.09 | $6.18 | x |
| 2010-12-31 | $5.95 | $6.18 | x |
| 2011-12-31 | $2.64 | $6.18 | x |
| 2012-12-31 | $0.93 | $6.18 | x |
| 2013-12-31 | $0.51 | $6.18 | x |
| 2014-12-31 | $-0.49 | $6.18 | x |
| 2015-12-31 | $-0.34 | $6.18 | x |
| 2016-12-31 | $0.26 | $6.18 | x |
| 2017-12-31 | $0.13 | $6.18 | x |
| 2018-12-31 | $2.20 | $6.18 | x |
| 2019-12-31 | $0.64 | $6.18 | x |
| 2020-12-31 | $1.66 | $6.18 | x |
| 2021-12-31 | $2.12 | $6.18 | x |
| 2022-12-31 | $1.20 | $6.18 | x |
| 2023-12-31 | $1.57 | $6.18 | x |
| 2024-12-31 | $1.01 | $6.18 | x |
| 2025-12-31 | $1.19 | $6.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DiaMedica Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -58.39%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-58.39%) is above the historical average (-128.22%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.00% | -1889.02% | 0.16x | 0.00x | $-534.00K |
| 2005 | -41.61% | -820.13% | 0.05x | 1.11x | $-261.21K |
| 2006 | -119.04% | -3022.96% | 0.04x | 1.08x | $-843.38K |
| 2007 | -57.41% | -1452.78% | 0.04x | 1.07x | $-2.74 Million |
| 2008 | -66.68% | 0.00% | 0.00x | 1.08x | $-2.13 Million |
| 2009 | -232.47% | 0.00% | 0.00x | 1.19x | $-2.54 Million |
| 2010 | -50.05% | 0.00% | 0.00x | 1.07x | $-5.12 Million |
| 2011 | -110.83% | 0.00% | 0.00x | 1.06x | $-7.20 Million |
| 2012 | -443.83% | 0.00% | 0.00x | 1.70x | $-10.28 Million |
| 2013 | -536.39% | 0.00% | 0.00x | 2.10x | $-7.55 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.66 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.32 Million |
| 2016 | -178.42% | 0.00% | 0.00x | 1.50x | $-2.35 Million |
| 2017 | -533.17% | 0.00% | 0.00x | 2.26x | $-4.34 Million |
| 2018 | -33.68% | -1146.80% | 0.03x | 1.08x | $-7.44 Million |
| 2019 | -139.81% | 0.00% | 0.00x | 1.19x | $-11.41 Million |
| 2020 | -47.25% | 0.00% | 0.00x | 1.08x | $-14.89 Million |
| 2021 | -30.87% | 0.00% | 0.00x | 1.03x | $-17.99 Million |
| 2022 | -42.97% | 0.00% | 0.00x | 1.08x | $-16.86 Million |
| 2023 | -37.96% | 0.00% | 0.00x | 1.06x | $-24.49 Million |
| 2024 | -60.03% | 0.00% | 0.00x | 1.14x | $-28.52 Million |
| 2025 | -58.39% | 0.00% | 0.00x | 1.09x | $-38.38 Million |
Industry Comparison
This section compares DiaMedica Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DiaMedica Therapeutics Inc (DMAC) | $56.11 Million | 0.00% | 0.09x | $332.99 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal… Read more